People
People who have managed to garner a large following on sites like Twitter, Facebook, Instagram, and the like have quite a bit of pull within said following. These “microcelebrities” are now a subject of interest for pharmaceutical companies who are looking for new ways to advertise their products.
“Humira is an anti-TNF monoclonal antibody that currently treats Crohn’s disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis,” quotes Humira developer AbbVie’s website. Those, plus other unlisted ailments, total at 15 conditions treated by only one drug.
At least one U.S. researcher who was in touch with He Jiankui and his team speculates that the second pregnancy may involve a baby or babies whose PCSK9 gene was editing using CRISPR. PCSK9 is involved in control of cholesterol.
The year 2018 saw a number of significant triumphs in the biopharma industry – increased numbers of drug approvals and near record-shattering IPOs, but the industry also saw its share of blemishes and black eyes from various corners of the globe.
The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.
Shareholders raise concern over the fairness of the reverse merger and question potential conflicts of interest of OvaScience’s co-founder.
On November 28, 2018, PCT Europe announced to its attendees that the Society for Clinical Research Sites’ late founder, Christine Pierre, was awarded the 2018 Lifetime Achievement Award.
Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the report does believe there are good reasons to be.
PRESS RELEASES